Skip to main content
Top
Published in: Journal of Genetic Counseling 1/2014

01-02-2014 | Original Research

Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors

Author: Stephanie A. Cohen

Published in: Journal of Genetic Counseling | Issue 1/2014

Login to get access

Abstract

An electronic survey of the National Society of Genetic Counselors Cancer Special Interest Group was conducted in July 2011 to assess Lynch syndrome tumor screening programs and identify barriers to implementation. Over half of respondents (52.8 %) reported having a routine Lynch syndrome tumor screening protocol for newly diagnosed colon and/or endometrial cancers, and approximately half of these used a universal approach. There was an increase in the number of those screening over time, especially in the past 3 years. Tumor screening methods varied; 34/53 (64.2 %) started with immunohistochemistry, 11/53 (20.8 %) started with microsatellite instability testing and 8/53 (15.1 %) performed both on newly diagnosed colorectal tumors. Just 21.7 % (23/106) of respondents indicated they have a tumor screening program in place for newly diagnosed endometrial cancers. Written consent is rarely obtained (7.1 %) and the method of how results were returned to the patient was variable among respondents. Prevalent barriers to implementation were concern about cost, bringing key players together and convincing medical staff of the necessity. Use of Lynch syndrome tumor screening is in clinical practice, but protocols vary widely. This survey provides a glimpse of current practices and common barriers, and identifies the need for tumor screening algorithms with outcomes data.
Literature
go back to reference Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2010). Risks of lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201. doi:10.1093/jnci/djp473.PubMedCrossRef Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2010). Risks of lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201. doi:10.​1093/​jnci/​djp473.PubMedCrossRef
go back to reference Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763. doi:10.1056/NEJMoa053493.PubMedCrossRef Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., et al. (2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. The New England Journal of Medicine, 354(26), 2751–2763. doi:10.​1056/​NEJMoa053493.PubMedCrossRef
go back to reference Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242. doi:10.1111/j.1399-0004.2008.01035.x.PubMedCrossRef Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242. doi:10.​1111/​j.​1399-0004.​2008.​01035.​x.PubMedCrossRef
go back to reference Beamer, L., Grant, M., Espenschied, C., Blazer, K., Hampel, H., Weitzel, J., et al. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology, 30(10), 1058–1063.PubMedCrossRef Beamer, L., Grant, M., Espenschied, C., Blazer, K., Hampel, H., Weitzel, J., et al. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology, 30(10), 1058–1063.PubMedCrossRef
go back to reference Bellcross, C. A., Bedrosian, S. R., Daniels, E., Duquette, D., Hampel, H., Jasperson, K., et al. (2012). Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 14(1), 152–162.PubMedCentralPubMedCrossRef Bellcross, C. A., Bedrosian, S. R., Daniels, E., Duquette, D., Hampel, H., Jasperson, K., et al. (2012). Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 14(1), 152–162.PubMedCentralPubMedCrossRef
go back to reference Bouzourene, H., Hutter, P., Losi, L., Martin, P., & Benhattar, J. (2010). Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Familial Cancer, 9(2), 167–172. doi:10.1007/s10689-009-9302-4.PubMedCrossRef Bouzourene, H., Hutter, P., Losi, L., Martin, P., & Benhattar, J. (2010). Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Familial Cancer, 9(2), 167–172. doi:10.​1007/​s10689-009-9302-4.PubMedCrossRef
go back to reference Burks, R. T., Kessis, T. D., Cho, K. R., & Hedrick, L. (1994). Microsatellite instability in endometrial carcinoma. Oncogene, 9(4), 1163–1166.PubMed Burks, R. T., Kessis, T. D., Cho, K. R., & Hedrick, L. (1994). Microsatellite instability in endometrial carcinoma. Oncogene, 9(4), 1163–1166.PubMed
go back to reference Burt, R. W., Giardiello, F. M., Jasperson, K., Lynch, P. M., Steinbach, G. (2011). NCCN Guidelines v.2.2011 Colorectal Cancer Screening. www.nccn.org. Accessed 3-1-2012 2012. Burt, R. W., Giardiello, F. M., Jasperson, K., Lynch, P. M., Steinbach, G. (2011). NCCN Guidelines v.2.2011 Colorectal Cancer Screening. www.​nccn.​org. Accessed 3-1-2012 2012.
go back to reference Chubak, B., Heald, B., & Sharp, R. R. (2011). Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(4), 356–360. doi:10.1097/GIM.0b013e31820aee09. Chubak, B., Heald, B., & Sharp, R. R. (2011). Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(4), 356–360. doi:10.​1097/​GIM.​0b013e31820aee09​.
go back to reference Cunningham, J. M., Christensen, E. R., Tester, D. J., Kim, C.-Y., Roche, P. C., Burgart, L. J., et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Research, 58(15), 3455–3460.PubMed Cunningham, J. M., Christensen, E. R., Tester, D. J., Kim, C.-Y., Roche, P. C., Burgart, L. J., et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Research, 58(15), 3455–3460.PubMed
go back to reference Des Guetz, G., Schischmanoff, O., Nicolas, P., Perret, G.-Y., Morere, J.-F., & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. European Journal of Cancer, 45(10), 1890–1896. doi:10.1016/j.ejca.2009.04.018.PubMedCrossRef Des Guetz, G., Schischmanoff, O., Nicolas, P., Perret, G.-Y., Morere, J.-F., & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. European Journal of Cancer, 45(10), 1890–1896. doi:10.​1016/​j.​ejca.​2009.​04.​018.PubMedCrossRef
go back to reference Dove-Edwin, I., Sasieni, P., Adams, J., & Thomas, H. J. (2005). Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 331(7524), 1047. doi:10.1136/bmj.38606.794560.EB.PubMedCrossRef Dove-Edwin, I., Sasieni, P., Adams, J., & Thomas, H. J. (2005). Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 331(7524), 1047. doi:10.​1136/​bmj.​38606.​794560.​EB.PubMedCrossRef
go back to reference EGAPP. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.CrossRef EGAPP. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.CrossRef
go back to reference Fitzgibbons, R. J., Jr., Lynch, H. T., Stanislav, G. V., Watson, P. A., Lanspa, S. J., Marcus, J. N., et al. (1987). Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Annals of Surgery, 206(3), 289–295.PubMedCrossRef Fitzgibbons, R. J., Jr., Lynch, H. T., Stanislav, G. V., Watson, P. A., Lanspa, S. J., Marcus, J. N., et al. (1987). Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Annals of Surgery, 206(3), 289–295.PubMedCrossRef
go back to reference Gudgeon, J., Williams, J., Burt, R. W., Samowitz, W., Snow, G., & Williams, M. (2011). Lynch syndrome screening implementation: business analysis by a healthcare system. The American Journal of Managed Care, 17(8), e288–e300.PubMed Gudgeon, J., Williams, J., Burt, R. W., Samowitz, W., Snow, G., & Williams, M. (2011). Lynch syndrome screening implementation: business analysis by a healthcare system. The American Journal of Managed Care, 17(8), e288–e300.PubMed
go back to reference Hall, M. J. (2010). Counterpoint: implementing population genetic screening for lynch syndrome among newly diagnosed colorectal cancer patients—will the ends justify the means? Journal of the National Comprehensive Cancer Network, 8(5), 606–611. Hall, M. J. (2010). Counterpoint: implementing population genetic screening for lynch syndrome among newly diagnosed colorectal cancer patients—will the ends justify the means? Journal of the National Comprehensive Cancer Network, 8(5), 606–611.
go back to reference Hampel, H. (2010). Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network, 8(5), 597–601.PubMed Hampel, H. (2010). Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network, 8(5), 597–601.PubMed
go back to reference Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860. doi:10.1056/NEJMoa043146.PubMedCrossRef Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860. doi:10.​1056/​NEJMoa043146.PubMedCrossRef
go back to reference Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J.-P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later Age of onset. Gastroenterology, 129(2), 415–421. doi:10.1053/j.gastro.2005.05.011.PubMed Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J.-P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later Age of onset. Gastroenterology, 129(2), 415–421. doi:10.​1053/​j.​gastro.​2005.​05.​011.PubMed
go back to reference Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810–7817. doi:10.1158/0008-5472.CAN-06-1114.PubMedCrossRef Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 66(15), 7810–7817. doi:10.​1158/​0008-5472.​CAN-06-1114.PubMedCrossRef
go back to reference Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2008). Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology, 26(35), 5783–5788. doi:10.1200/JCO.2008.17.5950.PubMedCrossRef Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2008). Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology, 26(35), 5783–5788. doi:10.​1200/​JCO.​2008.​17.​5950.PubMedCrossRef
go back to reference Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences, 95(12), 6870–6875.CrossRef Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences, 95(12), 6870–6875.CrossRef
go back to reference Jarvinen, H. J., Renkonen-Sinisalo, L., Aktan-Collan, K., Peltomaki, P., Aaltonen, L. A., & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology, 27(28), 4793–4797. doi:10.1200/JCO.2009.23.7784.PubMedCrossRef Jarvinen, H. J., Renkonen-Sinisalo, L., Aktan-Collan, K., Peltomaki, P., Aaltonen, L. A., & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology, 27(28), 4793–4797. doi:10.​1200/​JCO.​2009.​23.​7784.PubMedCrossRef
go back to reference Leenen, C. H. M., van Lier, M. G. F., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et al. (2012). Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecologic Oncology, 125(2), 414–420. doi:10.1016/j.ygyno.2012.01.049.PubMedCrossRef Leenen, C. H. M., van Lier, M. G. F., van Doorn, H. C., van Leerdam, M. E., Kooi, S. G., de Waard, J., et al. (2012). Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years. Gynecologic Oncology, 125(2), 414–420. doi:10.​1016/​j.​ygyno.​2012.​01.​049.PubMedCrossRef
go back to reference Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158–5164. doi:10.1200/JCO.2007.10.8597.PubMedCrossRef Lu, K. H., Schorge, J. O., Rodabaugh, K. J., Daniels, M. S., Sun, C. C., Soliman, P. T., et al. (2007). Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. Journal of Clinical Oncology, 25(33), 5158–5164. doi:10.​1200/​JCO.​2007.​10.​8597.PubMedCrossRef
go back to reference Lynch, H. T. (1999). Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenetics and Cell Genetics, 86(2), 130–135.PubMedCrossRef Lynch, H. T. (1999). Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenetics and Cell Genetics, 86(2), 130–135.PubMedCrossRef
go back to reference Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 12(2), 93–104. doi:10.1097/GIM.0b013e3181cd666c.PubMedCrossRef Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 12(2), 93–104. doi:10.​1097/​GIM.​0b013e3181cd666c​.PubMedCrossRef
go back to reference Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.PubMedCentralPubMedCrossRef Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.PubMedCentralPubMedCrossRef
go back to reference Pappa, K. I., Choleza, M., Markaki, S., Giannikaki, E., Kyroudi, A., Vlachos, G., et al. (2006). Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecologic Oncology, 100(3), 596–600. doi:10.1016/j.ygyno.2005.09.029.PubMedCrossRef Pappa, K. I., Choleza, M., Markaki, S., Giannikaki, E., Kyroudi, A., Vlachos, G., et al. (2006). Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecologic Oncology, 100(3), 596–600. doi:10.​1016/​j.​ygyno.​2005.​09.​029.PubMedCrossRef
go back to reference Peres, J. (2010). To screen or not to screen for Lynch syndrome. Journal of the National Cancer Institute, 102(18), 1382–1384. Peres, J. (2010). To screen or not to screen for Lynch syndrome. Journal of the National Cancer Institute, 102(18), 1382–1384.
go back to reference Pinol, V., Castells, A., Andreu, M., Castellvi-Bel, S., Alenda, C., Llor, X., et al. (2005). Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Journal of the American Medical Association, 293(16), 1986–1994. doi:10.1001/jama.293.16.1986.PubMedCrossRef Pinol, V., Castells, A., Andreu, M., Castellvi-Bel, S., Alenda, C., Llor, X., et al. (2005). Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Journal of the American Medical Association, 293(16), 1986–1994. doi:10.​1001/​jama.​293.​16.​1986.PubMedCrossRef
go back to reference Ramsoekh, D., Wagner, A., van Leerdam, M., Dooijes, D., Tops, C., Steyerberg, E., et al. (2009). Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, 7(1), 17.PubMedCentralPubMedCrossRef Ramsoekh, D., Wagner, A., van Leerdam, M., Dooijes, D., Tops, C., Steyerberg, E., et al. (2009). Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, 7(1), 17.PubMedCentralPubMedCrossRef
go back to reference Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., & Boyd, J. (1993). Genetic instability of microsatellites in endometrial carcinoma. Cancer Research, 53(21), 5100–5103.PubMed Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., & Boyd, J. (1993). Genetic instability of microsatellites in endometrial carcinoma. Cancer Research, 53(21), 5100–5103.PubMed
go back to reference Salvesen, H. B., Kumar, R., Stefansson, I., Angelini, S., MacDonald, N., Smeds, J., et al. (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer, 115(6), 930–934. doi:10.1002/ijc.20702.CrossRef Salvesen, H. B., Kumar, R., Stefansson, I., Angelini, S., MacDonald, N., Smeds, J., et al. (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer, 115(6), 930–934. doi:10.​1002/​ijc.​20702.CrossRef
go back to reference Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261–269. doi:10.1056/NEJMoa052627.PubMedCrossRef Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England Journal of Medicine, 354(3), 261–269. doi:10.​1056/​NEJMoa052627.PubMedCrossRef
go back to reference Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. Journal of Molecular Diagnostics, 10(4), 293–300. doi:10.2353/jmoldx.2008.080031.PubMedCrossRef Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. Journal of Molecular Diagnostics, 10(4), 293–300. doi:10.​2353/​jmoldx.​2008.​080031.PubMedCrossRef
go back to reference Shia, J., Stadler, Z., Weiser, M. R., Rentz, M., Gonen, M., Tang, L. H., et al. (2011). Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? The American Journal of Surgical Pathology, 35(3), 447–454. doi:10.1097/PAS.0b013e31820a091d. Shia, J., Stadler, Z., Weiser, M. R., Rentz, M., Gonen, M., Tang, L. H., et al. (2011). Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? The American Journal of Surgical Pathology, 35(3), 447–454. doi:10.​1097/​PAS.​0b013e31820a091d​.
go back to reference Sjursen, W., Haukanes, B. I., Grindedal, E. M., Aarset, H., Stormorken, A., Engebretsen, L. F., et al. (2010). Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. Journal of Medical Genetics, 47(9), 579–585. doi:10.1136/jmg.2010.077677.PubMedCentralPubMedCrossRef Sjursen, W., Haukanes, B. I., Grindedal, E. M., Aarset, H., Stormorken, A., Engebretsen, L. F., et al. (2010). Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. Journal of Medical Genetics, 47(9), 579–585. doi:10.​1136/​jmg.​2010.​077677.PubMedCentralPubMedCrossRef
go back to reference Stormorken, A. T., Clark, N., Grindedal, E., Maehle, L., & Moller, P. (2007). Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scandinavian Journal of Gastroenterology, 42(5), 611–617. doi:10.1080/00365520601010230.PubMedCrossRef Stormorken, A. T., Clark, N., Grindedal, E., Maehle, L., & Moller, P. (2007). Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scandinavian Journal of Gastroenterology, 42(5), 611–617. doi:10.​1080/​0036552060101023​0.PubMedCrossRef
go back to reference Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268. doi:10.1093/jnci/djh034.PubMedCentralPubMedCrossRef Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268. doi:10.​1093/​jnci/​djh034.PubMedCentralPubMedCrossRef
go back to reference Vasen, H., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Diseases of the Colon & Rectum, 34(5), 424–425.CrossRef Vasen, H., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Diseases of the Colon & Rectum, 34(5), 424–425.CrossRef
go back to reference Vasen, H., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.PubMedCrossRef Vasen, H., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.PubMedCrossRef
go back to reference Weissman, S., Burt, R., Church, J., Erdman, S., Hampel, H., Holter, S., et al. (2012). Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 21(4), 484–493. doi:10.1007/s10897-011-9465-7.PubMedCrossRef Weissman, S., Burt, R., Church, J., Erdman, S., Hampel, H., Holter, S., et al. (2012). Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Journal of Genetic Counseling, 21(4), 484–493. doi:10.​1007/​s10897-011-9465-7.PubMedCrossRef
go back to reference Williams, J., & Williams, M. (2011). Informed consent and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(9), 848–849.PubMedCrossRef Williams, J., & Williams, M. (2011). Informed consent and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine, 13(9), 848–849.PubMedCrossRef
go back to reference Zhang, L. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. Journal of Molecular Diagnostics, 10(4), 301–307. doi:10.2353/jmoldx.2008.080062.PubMedCrossRef Zhang, L. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. Journal of Molecular Diagnostics, 10(4), 301–307. doi:10.​2353/​jmoldx.​2008.​080062.PubMedCrossRef
Metadata
Title
Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors
Author
Stephanie A. Cohen
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 1/2014
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-013-9603-5

Other articles of this Issue 1/2014

Journal of Genetic Counseling 1/2014 Go to the issue